Catalent and Galapagos Collaborate on Decentralized CAR-T Manufacturing; Kindeva Secures $129M Contract for Nerve Agent Antidote

Catalent and Galapagos Partnership:

Catalent and Galapagos have announced a collaboration to support decentralized manufacturing for clinical trials of GLPG5101, Galapagos’ investigational CAR-T therapy for relapsed/refractory non-Hodgkin lymphoma (NHL)14.
The manufacturing will be conducted at Catalent’s cell therapy manufacturing site in Princeton, New Jersey, to facilitate production for trials in New Jersey, New York, and surrounding areas14.

Decentralized Manufacturing Approach:

Galapagos’ decentralized platform allows cell therapies to be manufactured near cancer treatment centers, aiming to improve patient outcomes by reducing vein-to-vein time to a median of seven days, eliminating the need for cryopreservation or bridging therapy14.

Kindeva Drug Delivery Contract:

Kindeva Drug Delivery’s subsidiary Meridian Medical Technologies has secured a $129 million contract to supply DuoDote, an antidote for chemical nerve agents, to the US Strategic National Stockpile25.
DuoDote is an FDA-approved dual-chamber autoinjector containing atropine and pralidoxime chloride, indicated for the treatment of poisoning by organophosphorus nerve agents and insecticides2.

Sources:

1. https://www.catalent.com/catalent-news/catalent-announces-collaboration-with-galapagos-to-further-expand-galapagos-decentralized-car-t-manufacturing-network-in-the-u-s/

2. https://www.kindevadd.com/news/kindeva-drug-delivery-awarded-up-to-129-million-to-supply-duodote-autoinjectors-to-the-strategic-national-stockpile/

4. https://www.pharmamanufacturing.com/industry-news/news/55262204/catalent-galapagos-partner-on-decentralized-car-t-manufacturing

5. https://endpts.com/wp-content/uploads/2021/06/mf-FE.jpg?sa=X&ved=2ahUKEwiJh7fQ7JaLAxUeRzABHSuMRAQB16BAgBEAI